Target
topoisomerase I
62 abstracts
Abstract
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, UNC Lineberger Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Emory University Hospital,
Abstract
NRG Oncology/RTOG 0848: Results after adjuvant chemotherapy +/- chemoradiation for patients with resected periampullary pancreatic adenocarcinoma (PA).Org: Rush University Medical Center, NRG Oncology SDMC/ACR, Mount Sinai Medical Center, University of Maryland, Baltimore, MD, Brown University School of Medicine-Rhode Island Hospital,
Abstract
Evaluation of the safety, pharmacokinetics, and efficacy of JSKN003 in patients with advanced solid tumors: A phase I/II clinical study.Org: Department of Breast Surgery, Sun Yat-sen Memorial Hospital, 2nd Hospital, Zhejiang University School of Medicine, Department of Medical Oncology, Xuzhou Central Hospital,
Abstract
ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome.Org: Gustave Roussy Cancer Center, Biostatistics Unit, Hopital Cochin, Chi Creteil, Centre François Baclesse,
Abstract
Sacituzumab tirumotecan (SKB264/MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study.Org: Sun Yat-sen University Cancer Center, Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Jilin Cancer Hospital, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine,
Abstract
YL202/BNT326, a HER3-targeted ADC, in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase I trial.Org: Summit Cancer Centers, BRCR Global, Karmanos Cancer Center,
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, UPMC Hillman Cancer Center, NSABP Foundation, Inc. Pathology Lab,
Abstract
Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: A randomized phase II trial.Org: Haeundae Paik Hospital,
Abstract
Efficacy of fadraciclib (CYC065), a novel dual CDK2/9 inhibitor, on patient-derived models of colorectal cancer.Org: Cyclacel Pharmaceuticals Inc,
Abstract
Efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after developing resistance to several TKIs: A multicentered retrospective study.Org: Department of Orthopaedics, Zhejiang University, Hangzhou, China, Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, China, Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China, Peking University People’s Hospital, Beijing, China,
Abstract
Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.Org: Broward Health, Genmab US, Inc.,
Abstract
METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer: Multimodal surgical treatment versus systemic chemotherapy alone—A prospective randomized controlled multicenter phase III trial.Org: Amsterdam UMC Location University of Amsterdam, University Hospital Essen West German Cancer Center,
Abstract
Neoadjuvant chemotherapy with FOLFOXIRI plus lateral lymph nodes dissection for the treatment of resectable rectal cancer with lateral lymph node metastasis: A single-arm, investigator-initiated, phase II trial.Org: State Key Laboratory of Molecular Oncology and Department of Radiation Oncology, Comprehensive Third Ward, Cancer Institute & Hospital,
Abstract
A phase II study of cadonilimab plus mFOLFIRINOX as induction therapy for locally advanced pancreatic adenocarcinoma (LAPC).Org: Nanjing, China, Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital,
Abstract
REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC).Org: Section of Gynecologic Oncology,
Abstract
Comparison of prophylactic effects for chemotherapy-induced neutropenia between same-day vs next-day administration of pegteograstim in chemotherapy regimen composed of day 1 intensive myelosuppressive agent: A randomized phase III trial (CONCISE, KCSG PC22-11).Org: Hanyang University Seoul Hospital, Yangsan, South Korea, Uijeongbu St. Mary’s Hospital, Uijeongbu, South Korea, Dong-A University College of Medicine,
Abstract
Efficacy and safety of luveltamab tazevibulin vs investigator’s choice of chemotherapy in patients with recurrent platinum-resistant ovarian cancer (PROC) expressing folate receptor alpha (FRα): The REFRaME-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study.Org: Medical Oncology Service, Vall d’Hebron Institute of Oncology, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain, Yonsei Cancer Center and Severance Hospital, Seoul, South Korea, Department of Gynaecology, Obstetrics and Neonatology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic, The Royal Hospital for Women, Sydney, Australia, Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA,
Abstract
Phase 3 MIRASOL (GOG 3045/ENGOT-ov55) trial: Mirvetuximab soravtansine (MIRV) vs. investigator’s choice chemotherapy (ICC) in older patients with platinum-resistant ovarian cancer (PROC) and high folate receptor-alpha (FRα) expression.Org: Istituto Europeo Oncologia, Community Health Network, Inc, Wielkopolskie Centrum Onkologii, Department of Obstetrics and Gynecology, Faculty of Medicine,
Abstract
Phase I dose escalation and pharmacokinetics clinical trial of mitoxantrone hydrochloride liposome in children with relapsed and refractory solid tumors.Org: Wuhan Children's Hospital,
Abstract
N9: Pilot study of novel shortened induction for high-risk neuroblastoma.Org: Memorial Sloan Kettering Cancer Center,
Abstract
IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC).Org: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Jilin Cancer Hospital, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Hospital Universitario 12 de Octubre,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Effect of p16 immunohistochemical expression (exp) on irinotecan in metastatic colorectal cancer (mCRC): A translational analysis of the TRIBE and TRIBE2 studies.Org: CdC Poliambulanza, AULSS8 Berica,
Abstract
First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas.Org: Villalba General Hospital, Servicio de Cirugía General y Digestiva, Hospitals Universitario Vall d'Hebron, Pediatric Surgery Department, Universitat Politècnica de Catalunya (UPC),
Abstract
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.Org: Royal Marsden/Institute of Cancer Research, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Sir Bobby Robson Cancer Trial Research Centre,
Abstract
A phase II study of liposomal irinotecan-based chemotherapy with or without PD-1 inhibitor in patients with unresectable locally advanced or metastatic biliary tract cancer.Org: Zhejiang Chinese Medical University,
Abstract
Eribulin and irinotecan for refractory or recurrent Ewing sarcoma: A retrospective study.Org: Peking University People’s Hospital, Beijing, China,
Abstract
Updated efficacy and safety results from the phase Ib/II study of surufatinib combined with camrelizumab and chemotherapy in patients with advanced colorectal cancer.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Jiangsu Cancer Hospital, Nanjing, China,
Abstract
A multicenter phase II study of modified FOLFIRINOX for first-line treatment for advanced urachal cancer (ULTMA; KCSG GU20-03).Org: Yonesi University College of Medicine, Yangsan Si, South Korea, Daejeon, South Korea,
Abstract
Effect of triplet regimen (single-agent chemotherapy plus anti-PD-1 antibody and tyrosine kinase inhibitors) on survival compared to chemotherapy in the second-line treatment of advanced biliary tract cancer: A retrospective analysis.Org: the Naval Medical University,
Abstract
Irinotecan and temozolomide combined with dasatinib and rapamycin for patients with relapsed or refractory neuroblastoma: Results of the prospective randomized RIST trial.Org: University Hospital of Regensburg, University Medicine Greifswald, Pediatric Hematology and Oncology, University Medical Center Dresden, University of Jena, University Children's Hospital,
Abstract
Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).Org: Institute of Clinical Medicine, University of Oslo, Institute of Clinical Sciences, Department of Surgery, The Sahlgrenska Academy, University of Gothenburg, Department of Biomedical and Clinical Sciences, Linköping University, Clatterbridge Cancer Centre NHS FT, School of Health Sciences, University of Skövde,
Abstract
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.Org: Memorial Sloan Kettering Cancer Center, Azienda Ospedaliera Universitaria Integrata di Verona, Hospital Universitario Miguel Servet, Centre Léon Bérard, Masaryk Memorial Cancer Institute,
Abstract
Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.Org: Novartis Pharma AG, F. Hoffmann-La Roche Ltd, Exelixis, Inc., VBL Therapeutics, Dana-Farber Cancer Institute,
Abstract
Preliminary results from a first-in-human study of ESG401, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors.Org: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, Department of Medical Oncology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China, Tianjin cancer hospital ,China, Tianjin, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
The impact of renin-angiotensin-aldosterone system inhibitors on immune checkpoint inhibitor-associated adverse cardiovascular events.Org: National Taiwan University Hospital Yunlin Branch, Mount Auburn Hospital, Harvard Medical School, Cambridge University Hospitals NHS Foundation Trust, Taipei TzuChi Hospital,
Abstract
Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC).Org: Abramson Cancer Center at the University of Pennsylvania, University of Pennsylvania, Department of Biostatistics, Epidemiology, and Informatics,
Abstract
A phase 2 single-arm study of berzosertib in combination with irinotecan in patients with progressive TP53 mutant gastric and gastro-esophageal junction cancer.Org: Vanderbilt University Medical Center, Hunstman Cancer Hospital, University of Utah Health, University of Utah, University of California Irvine, University of Pittsburgh Medical Center (UPMC),
Abstract
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,
Abstract
MicroOrganoSpheres as a clinically applicable precision oncology platform for the discovery of novel therapies in colorectal cancer.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Medical Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Medicine, Division of Medical Oncology, University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center,
Abstract
A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.Org: University of Florida/UF Health Cancer Center, University of Florida Health Cancer Center, Orlando Health Cancer Institute, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics,
Abstract
Efficacy and safety of irinotecan-eluting HepaSphere transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable colorectal liver metastases.Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital & Institute,
Abstract
Ex-vivo analysis of programmed cell death on fibrolamellar carcinoma.Org: Rush University Medical School, FibroFighters Foundation, Nagourney Cancer Institute, FibroFighters.org, Rush University Medical Center,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,
Abstract
Brain metastasis burden and management in small cell lung cancer: An analysis of 8705 patients.Org: University of Toronto, Princess Margaret Cancer Centre, Sunnybrook Odette Cancer Centre, University Health Network, St. Michael's Hospital and University of Toronto,
Abstract
Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study.Org: Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), Cliniques Universitaires Saint-Luc, Department of Gastroenterology, Division of Digestive Oncology, Centre Léon Bérard,
Abstract
Phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Center GF Leclerc, Georges-François Leclerc Cancer Center, Georges François Leclerc Cancer Center – UNICANCER, Dijon, France, William Morey Hospital,
Abstract
Anticancer–drug-induced interstitial lung disease (DIILD): With great power comes great responsibility.Org: Syneos Health, Morrisville, NC, NC Medical Research, Gurugram, Indiana University – Purdue University Indianapolis,
Abstract
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).Org: Institut Gustave Roussy, Villejuif, France, Hospital Universitario 12 de Octubre, Madrid, Spain, Spain,
Abstract
A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors.Org: Edison Oncology Holding Corp., Valent Technologies LLC, Cincinnati Children's Hospital Medical Center, Levine Children's Hospital, Sarah Cannon Research Hospital HCA,
Abstract
Updated results of the phase 1 I-FLOAT trial: Safety and efficacy of combining genotype-guided irinotecan with 5FU, leucovorin, oxaliplatin and docetaxel (gFOLFOXIRITAX) in advanced upper GI cancers.Org: University of Chicago Medical Center, Chicago, IL, University of Chicago, Department of Medicine, Icahn School of Medicine at Mount Sinai, Section of Hematology & Oncology, University of Illinois Chicago,
Abstract
Overall survival in patients with recurrent glioblastomas with combination chemotherapy and tumor treating fields (TTF).Org: University of Texas Health Science Center at Houston, University of Texas Health Science Center at Houston, McGovern Medical School,
Abstract
The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer.Org: Amplia Therapeutics, Melbourne, Australia, Australian Catholic University, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia,
Abstract
Establishing functional models of peritoneal carcinomatosis using MicroOrganoSphere (MOS) technology.Org: University of Texas MD Anderson Cancer Center, Xilis Inc, Xilis Inc., University of Texas at MD Anderson Cancer Center, Xilis, Inc.,
Abstract
Randomized phase 3 study of tarlatamab, a DLL3-targeting bispecific T-cell engager (BiTE), compared to standard of care in patients with relapsed small cell lung cancer (DeLLphi-304).Org: Hospital Universitario 12 de Octubre, CNIO-H120 Lung Cancer Unit, Ciberonc and Universidad Complutense, Madrid, Spain, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), The Christie NHS Foundation Trust, Division of Cancer Sciences, Manchester, United Kingdom, Fox Chase Cancer Center, Philadelphia, PA,
Abstract
IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).Org: Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University, Versailles, France, Institut Curie, Saint Cloud, France, Univ Rouen Normandie, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
Impact of COVID-19 pandemic on the treatment of prostate cancer in the Brazilian Public Health System.Org: LACOG - Latin American Cooperative Oncology Group, University of California, San Diego (UCSD), University of California at San Diego, Univeristy of California San Diego, Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil,
Abstract
Efficacy of STC-1010, a new allogenic cancer vaccine in colorectal cancer models.Org: Brenus Pharma, Clermont-Ferrand, France, Inovotion, Explicyte Immuno-Oncology, Institut de Recherche en Cancérologie de Montpellier, Center Georges François Leclerc,
Abstract
Hearing loss related outcomes post-lateral temporal bone resection and other oncologic treatment.Org: University of Texas MD Anderson Cancer Center, UT Health San Antonio, MD Anderson Cancer Center, Associates of Audiology, LLC,
Abstract
Predictors of resistance to trastuzumab deruxtecan (T-DXd) in esophagogastric adenocarcinoma (EGC).Org: Weill Cornell Medical Center/New York Presbyterian, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering/Weill Cornell Medical College, Moffitt Cancer Center, Memorial Sloan Kettering Cancer Center,
Abstract
Effect of upfront HSCT on patients with T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma at high risk of relapse: Single center retrospective observational study on minority rich population.Org: Jacobi Medical Center/Albert Einstein College of Medicine, Universal College of Medical Sciences, Montefiore Medical Center, Department of Medical Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, NY, Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine,
Abstract
Safety analysis of lurbinectedin versus topotecan in elderly patients.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Fondazione IRCCS - Istituto Nazionale dei Tumori, Fondazione Policlinico Gemelli IRCCS, Hospital Universitario Virgen de la Victoria, Institut Gustave Roussy,